XERS — Xeris Biopharma Holdings Income Statement
0.000.00%
Last trade - 00:00- $1.49bn
- $1.65bn
- $203.07m
- 45
- 39
- 97
- 64
Annual income statement for Xeris Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20.4 | 49.6 | 110 | 164 | 203 |
| Cost of Revenue | |||||
| Gross Profit | 11.1 | 36.3 | 87.6 | 135 | 166 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 105 | 165 | 193 | 211 | 239 |
| Operating Profit | -84.3 | -115 | -83.1 | -46.8 | -36.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -91.3 | -123 | -96.1 | -63.5 | -57.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -91.1 | -123 | -94.7 | -62.3 | -54.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -91.1 | -123 | -94.7 | -62.3 | -54.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -91.1 | -123 | -94.7 | -62.3 | -54.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.13 | -1.44 | -0.644 | -0.439 | -0.362 |